Al-royal Pharmaceutical Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Al-royal Pharmaceutical Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $71.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Al-royal Pharmaceutical Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $71.4K Trade | TransData Nexus

Al-royal Pharmaceutical Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $71.4K Total Trade · DGFT Verified

Al-royal Pharmaceutical Private Limited is an Indian pharmaceutical exporter with a total trade value of $71.4K across 3 products in 1 therapeutic categories. Based on 24 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Dacarbazine ($34.4K), Lenvatinib ($26.5K), Mercaptopurine ($10.5K).

Al-royal Pharmaceutical Private Limited — Export Portfolio & Destination Treemap

Al-royal Pharmaceutical Private Limited pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Al-royal Pharmaceutical Private Limited? — Company Overview & Market Position

Al-Royal Pharmaceutical Private Limited is an Indian pharmaceutical exporter established on August 1, 2017, in New Delhi, Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24290DL2017PTC321538. It operates as a private limited company, classified as a non-government entity, and is unlisted on stock exchanges. The authorized and paid-up capital of the company is ₹100,000.

The registered office is located at RZT-118, First Floor, Uttam Nagar Near Chawla Sweet, New Delhi, Delhi, 110059, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily focusing on the advanced oncology therapeutic category.

What Does Al-royal Pharmaceutical Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Dacarbazine$34.4K 2Lenvatinib$26.5K

Product Portfolio — Top 3 by Export Value

Al-royal Pharmaceutical Private Limited exports 3 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Dacarbazine	Advanced Oncology	$34.4K	9	2.4%	13
2	Lenvatinib	Advanced Oncology	$26.5K	11	1.2%	11
3	Mercaptopurine	Advanced Oncology	$10.5K	4	1.8%	9

Al-royal Pharmaceutical Private Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $71.4K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Al-royal Pharmaceutical Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Al-Royal Pharmaceutical Private Limited's manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company's operations are registered under the NIC code 2429, which pertains to the manufacture of other chemical products not elsewhere classified. This classification suggests that the company may engage in the production of various pharmaceutical products, potentially including oncology medications.

3Key Leadership

The company's leadership comprises two directors:

Ramjas Jain: Appointed on August 1, 2017.
Davinder Jain Kumar: Appointed on June 13, 2019.

The roles of Chief Executive Officer (CEO) and Chief Financial Officer (CFO) are not specified in the available public records.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Al-royal Pharmaceutical Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Al-Royal Pharmaceutical Private Limited's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available public records. The company's export activities, as per TransData Nexus proprietary trade data, indicate a total export value of $71,000 USD across 24 shipments, with products primarily in the advanced oncology therapeutic category. However, specific regulatory filings, approvals, and market access statuses in these regions are not publicly disclosed.

2Emerging Markets

The company's penetration into emerging markets in Africa, Latin America, and Southeast Asia is not detailed in the available public records. The absence of specific information regarding WHO prequalification or other certifications that would enable access to these markets suggests that Al-Royal Pharmaceutical Private Limited may not currently have a significant presence in these regions.

3Geographic Strategy

Al-Royal Pharmaceutical Private Limited's export activities, as indicated by TransData Nexus proprietary trade data, are concentrated in the advanced oncology therapeutic category, with a portfolio concentration of 100% in this area. The company's geographic strategy appears to be focused on markets that require specialized oncology medications. However, the lack of publicly available information on specific market diversification efforts or expansion plans suggests a potential concentration risk.

Al-royal Pharmaceutical Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Al-Royal Pharmaceutical Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data indicates shipments of finished pharmaceutical formulations, including oncology drugs, but does not provide information on FDA approvals or compliance status.

2WHO & EU GMP

There is no publicly available information confirming whether Al-Royal Pharmaceutical Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. These certifications are crucial for market access in various international regions, and the absence of such information may impact the company's ability to enter certain markets.

3CDSCO & Indian Regulatory

Al-Royal Pharmaceutical Private Limited is registered with the Central Drugs Standard Control Organisation (CDSCO) under the Corporate Identification Number (CIN) U24290DL2017PTC321538. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. The company's registered office address is RZT-118, First Floor, Uttam Nagar Near Chawla Sweet, New Delhi, Delhi, 110059, India.

Al-royal Pharmaceutical Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Al-Royal Pharmaceutical Private Limited operates in the advanced oncology therapeutic category, exporting finished pharmaceutical formulations such as Dacarbazine, Lenvatinib, and Mercaptopurine. The company's total export value is $71,000 USD across 24 shipments, with a portfolio concentration of 100% in this category. While specific market share data and a comprehensive list of competitors are not available, the company's focus on specialized oncology medications suggests competition with other pharmaceutical exporters in this niche market.

2Key Differentiators

Al-Royal Pharmaceutical Private Limited's key differentiator lies in its specialized focus on advanced oncology medications. The company's portfolio includes products such as Dacarbazine, Lenvatinib, and Mercaptopurine, indicating expertise in this therapeutic area. However, the lack of publicly available information on certifications like WHO prequalification or EU GMP may limit its competitive advantage in certain international markets.

3Strategic Position

Al-Royal Pharmaceutical Private Limited's current strategic direction appears to be centered on the export of specialized oncology medications. The company's portfolio concentration in this therapeutic area suggests a focused approach. However, the absence of publicly available information on diversification into generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services indicates that the company may not currently be pursuing these avenues. Future strategic directions may involve obtaining international certifications to enhance market access and exploring diversification opportunities to mitigate concentration risks.

Buyer Due Diligence Brief — Evaluating Al-royal Pharmaceutical Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Al-Royal Pharmaceutical Private Limited's track record in terms of export volume and consistency is not extensively documented in public records. The company's export data indicates shipments of finished pharmaceutical formulations, primarily in the advanced oncology category, but does not provide detailed insights into reliability indicators or consistency over time. The lack of publicly available information on certifications and regulatory approvals may impact the company's reliability as a supplier in certain markets.

2Certifications to Verify

Importers should verify the following certifications when considering Al-Royal Pharmaceutical Private Limited as a supplier:

FDA Facility Registration: To confirm compliance with U.S. regulations.
WHO Prequalification: To ensure acceptance in international markets.
EU GMP Certificate: To meet European Union standards.

Frequently Asked Questions — Al-royal Pharmaceutical Private Limited

How many pharmaceutical products does Al-royal Pharmaceutical Private Limited export from India?

Al-royal Pharmaceutical Private Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Dacarbazine ($34.4K), Lenvatinib ($26.5K), Mercaptopurine ($10.5K). Total export value is $71.4K.

What is Al-royal Pharmaceutical Private Limited's total pharmaceutical export value?

Al-royal Pharmaceutical Private Limited's total pharmaceutical export value is $71.4K, based on 24 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Al-royal Pharmaceutical Private Limited cover?

Al-royal Pharmaceutical Private Limited exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 3 products).

Get Full Al-royal Pharmaceutical Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.